https://www.forex-news.com/
Forex-News has been the world leading economy news website since 2005. It has been a joyful path full of changing variables in this changing world. During the last three years we have also covered some of the most important news regarding Bitcoin and other cryptocurrencies. Wherever the news are, we are there.
, Press Release: Novartis announces positive FDA -2- | message, Forex-News, Forex-News
Bitcoin
$36,385.65
+367.99
Ethereum
$1,252.67
+24.6
Litecoin
$144.11
+0.52
DigitalCash
$124.89
0
Monero
$161.85
+6.23
Nxt
$0.01
0
Ethereum Classic
$7.73
-0.04
Dogecoin
$0.01
-0

Press Release: Novartis announces positive FDA -2- | message

3
, Press Release: Novartis announces positive FDA -2- | message, Forex-News, Forex-News


, Press Release: Novartis announces positive FDA -2- | message, Forex-News, Forex-News

Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

For Novartis multimedia content, please visit

https://www.novartis.com/news/media-library

https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

1. US Department of Health and Human Services, Food and Drug Administration,

Center for Drug Evaluation and Research (CDER) and Center for Biologics

Evaluation and Research (CBER). Treatment for heart failure: endpoints

for drug development guidance for Industry. US Food and Drug

Administration. June 2019. Accessed July 17, 2019.

https://www.fda.gov/media/128372/download

2. Solomon S, McMurray J, Anand I, et al. Angiotensin neprilysin in heart

failure with preserved ejection fraction. N Engl J Med.

2019; 381: 1609-1620. doi: 10.1056 / NEJMoa1908655

3. Virani S, Alonso A, Benjamin E, et al. Heart disease and stroke

statistics-2020 update: a report from the American Heart Association.

Circulation. 2020; 141: e139-e596. doi: 10.1161 / CIR.0000000000000757

4. Shah K, Xu H, Matsouaka R, et al. Heart failure with preserved,

borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll

Cardiol. 2017; 70 (20): 2476-2486. doi: 10.1016 / j.jacc.2017.08.074

5. Solomon S, Rizkala A, Gong J, et al. Angiotensin receptor neprilysin

inhibition in heart failure with preserved ejection fraction: rationale

and design of the PARAGON-HF Trial. JACC Heart Fail. 2017; 5 (7): 471-482.

doi: 10.1016 / j.jchf.2017.04.013

6. Solomon S, Zile M, Pieske B, et al. The angiotensin receptor neprilysin

inhibitor LCZ696 in heart failure with preserved ejection fraction: a

Phase 2 double-blind randomized controlled trial. Lancet.

2012; 380 (9851): 1387-1395. doi: 10.1016 / S0140-6736 (12) 61227-6

7. McMurray J, Packer M, Desai A, et al. Angiotensin neprilysin inhibition

versus enalapril in heart failure. N Engl J Med. 2014; 371: 993-1004. doi:

10.1056 / NEJMoa1409077

8. Dunlay S, Roger V, Redfield M. Epidemiology of heart failure with

preserved ejection fraction. Nat Rev Cardiol. 2017; 14: 591-602.

doi: 10.1038 / nrcardio.2017.65

9. Pfeffer A, Shah A, Borlaug B. Heart failure with preserved ejection

fraction in perspective. Circ Res. 2019; 124: 1598-1617. doi:

10.1161 / CIRCRESAHA.119.313572

10. American Heart Association. Types of heart failure. Updated May 31, 2017.

Accessed June 3, 2020.

https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/types-of-heart-failure

11. Gheorghiade M, De Luca L, Fonarow G, et al. Pathophysiologic targets in

the early phase of acute heart failure syndromes. At J Cardiol.

2005; 96 (6A): 11G-17G.

12. Cheng R, Cox M, Neely M, et al. Outcomes in patients with heart failure

with preserved, borderline, and reduced ejection fraction in the Medicare

population. Am Heart J. 2014; 168 (5): 721-30. doi:

10.1016 / y.ahy.2014.07.008

13. Data on file. Novartis Pharmaceuticals Corp.

14. EMA. Entresto (sacubitril / valsartan). Summary of product characteristics.

Accessed July 2019.

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf

15. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis

Pharmaceuticals Corp; October 2019.

16. Chandra A, Lewis E, Claggertt B, et al. The Effects of

Sacubitril / Valsartan on Physical and Social Activity Limitations in Heart

Failure Patients: The PARADIGM-HF Trial. JAMA Cardiol. 2018; 3 (6): 498-505.

doi: 10.1001 / jamacardio.2018.0398

17. Desai AS, Claggett BL, Packer M, et al. Influence of sacubitril / valsartan

(LCZ696) on 30-day readmission after heart failure hospitalization. J Am

Coll Cardiol. 2016; 68 (3): 241-248. doi: 10.1016 / j.jacc.2016.04.047

18. Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with

LCZ696: a novel approach for the treatment of heart failure. Drug Discov

Today. 2012; 9 (4): e131-e139. doi: 10.1016 / j.ddstr.2013.11.002

https://c212.net/c/link/?t=0&l=en&o=2405309-1&h=457207487&u=http%3A%2F%2Fdx.doi.org%2F10.1016%2Fj.ddstr.2013.11.002&a=http % 3A% 2F% 2Fdx.doi.org% 2F10.1016% 2Fj.ddstr.2013.11.002

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Phil McNamara

Novartis External Communications Global Head, Cardio-Renal-Metabolism Communications

+41 61 324 2279 (direct) +41 79 510 8756 (mobile)

E-mail: anja.von_treskow@novartis.com E-mail: phil.mcnamara@novartis.com

Eric Althoff

Novartis US External Communications

+1 646 438 4335

E-mail: eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

December 15, 2020 19:17 ET (00:17 GMT)





, Press Release: Novartis announces positive FDA -2- | message, Forex-News, Forex-News

Get real time updates directly on you device, subscribe now.

, Press Release: Novartis announces positive FDA -2- | message, Forex-News, Forex-News

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More